Overview
Compare with MEDICINOVA INC, Selecta Biosciences (United States) or America Great Health, or pick any stock.
- TickerCANF on NYSE1
- Industrybiopharmaceutical1
- Headquartersפתח תקווה1
- Founded inIsrael1
- Websitewww.canfite.com
- Legal formlimited company, public company1
- Listed onNew York Stock Exchange (CANF), Tel Aviv Stock Exchange (CANF)1
- Incorporated inIsrael5
- Business address26 Ben Gurion Street, Ramat Gan, L3 52573465
- Filer categoryNon-accelerated filer5
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-2456.8%Operating margin4
-2426.7%Net margin4
-39.9%Revenue growth, 20254
-175.8%Return on equity4
-$9.0MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$6.7M
Out of $405.0K in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $405.0K | $674.0K | $743.0K |
| Research and development expenses | -$6.7M | -$5.8M | -$6.0M |
| General and administrative expenses | -$3.7M | -$3.0M | -$3.0M |
| Total operating expenses | -$10.4M | -$8.8M | -$8.9M |
| Operating loss | -$9.9M | -$8.1M | -$8.2M |
| Total financial income, net | $122.0K | $250.0K | $561.0K |
| Loss before taxes on income, Amount | -$9.8M | -$7.9M | -$7.6M |
| Net loss | -$9.8M | -$7.9M | -$7.6M |
| Basic net loss per share (in Dollars per share) | -$5.97 | -$10.86 | -$17.92 |
| Diluted net loss per share (in Dollars per share) | -$5.97 | -$10.86 | -$17.92 |
| Weighted average number of ordinary shares used in computing basic net loss per share | 1.6M shares | 725.3K shares | 426.1K shares |
| Weighted average number of ordinary shares used in computing diluted net loss per share | 1.6M shares | 725.3K shares | 426.1K shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.5M | $4.8M | |
| Short-term deposits | $3.0M | $3.1M | |
| Prepaid expenses, and other current assets | $900.0K | $1.1M | |
| Short-term investment | $1.0K | $5.0K | |
| Total current assets | $9.4M | $9.0M | |
| Operating lease right of use assets | $69.0K | $111.0K | |
| Property, plant and equipment, net | $5.0K | $27.0K | |
| Total non-current assets | $74.0K | $138.0K | |
| Total assets | $9.5M | $9.1M | |
| Trade payables | $1.2M | $618.0K | |
| Current maturity of operating lease liability | $56.0K | $53.0K | |
| Deferred revenues | $405.0K | $405.0K | |
| Other accounts payable | $1.1M | $976.0K | |
| Total current liabilities | $2.7M | $2.1M | |
| Long-term operating lease liability | $15.0K | $51.0K | |
| Deferred revenues | $1.2M | $1.6M | |
| Total non-current liabilities | $1.2M | $1.6M | |
| Additional paid-in capital | $180.7M | $170.7M | |
| Accumulated other comprehensive income | $1.1M | $1.1M | |
| Accumulated deficit | -$176.2M | -$166.4M | |
| Total shareholders equity | $5.6M | $5.4M | |
| Total liabilities and shareholders equity | $9.5M | $9.1M | |
| Ordinary shares, shares authorized | 14.0M shares | 6.7M shares | 3.3M shares |
| Ordinary shares, shares issued | 2.6M shares | 994.4K shares | |
| Ordinary shares, shares outstanding | 2.6M shares | 994.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$9.8M | -$7.9M | -$7.6M |
| Depreciation of property, plant and equipment | $24.0K | $7.0K | $15.0K |
| Reduction in the carrying amount of operating lease right of use asset | $42.0K | $37.0K | $94.0K |
| Share-based payment | $340.0K | $362.0K | $261.0K |
| Changes in fair value of short-term investment | $4.0K | $14.0K | -$11.0K |
| Financial expenses (income), net | $36.0K | $90.0K | -$222.0K |
| Change in prepaid expenses, and other current assets | $195.0K | -$109.0K | $184.0K |
| Decrease in operating lease liability | -$33.0K | -$32.0K | -$84.0K |
| Increase (decrease) in trade payable | $543.0K | $191.0K | -$469.0K |
| Decrease in deferred revenues | -$405.0K | -$349.0K | -$743.0K |
| Increase (decrease) in other accounts payable | $133.0K | $32.0K | $169.0K |
| Net cash used in operating activities | -$8.9M | -$7.6M | -$8.4M |
| Purchase of property, plant and equipment | -$2.0K | -$5.0K | -$2.0K |
| Maturity of short-term deposits, net | $1.5M | $500.0K | |
| Net cash provided by investing activities | -$2.0K | $1.5M | $498.0K |
| Issuance of ordinary shares due to ATM, net of issuance costs | $2.9M | $2.2M | |
| Issuance of ordinary shares and warrants, net of issuance costs | $6.7M | $4.5M | $9.1M |
| Net cash provided by financing activities | $9.6M | $6.7M | $9.1M |
| Exchange differences on balances of cash and cash equivalents | $10.0K | -$22.0K | $98.0K |
| Increase (decrease) in cash and cash equivalents | $703.0K | $547.0K | $1.3M |
| Lease liabilities arising from obtaining right-of-use-assets | $96.0K | $62.0K |
Timeline
- 1994Founded Founded in Israel1
Recent filings
- Oct 9, 2026424B3 PROSPECTUS
- Oct 9, 2026EFFECT
- Oct 9, 2026EFFECT
- Sep 25, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3
- Sep 25, 2026F-3 REGISTRATION STATEMENT
- Sep 11, 2026EFFECT
- Sep 11, 2026EFFECT
- Sep 10, 2026D
- Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 8, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 11 TO FORM F-1
- Sep 8, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 11 TO FORM F-1
- Sep 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.canfite.com1
- WikidataQ96482303
- SEC EDGARCIK 1536196
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCan Fite Biopharma on Wikidata
- 2
- 3Company websiteCan Fite Biopharma logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11